溶瘤病毒在逆转肿瘤免疫治疗耐药中的研究进展

doi:10.3760/cma.j.cn371439-20250727-00060

摘要/Abstract

摘要：

溶瘤病毒作为一种具有多重抗肿瘤机制的创新疗法，在逆转免疫治疗耐药中展现出显著潜力。溶瘤病毒的技术演进研究显示，其通过机制创新逐步克服肿瘤耐药性问题。在肿瘤免疫治疗领域，溶瘤病毒疗法正经历显著的技术演进，从早期的病毒选择性复制，发展为能携带多种免疫调节因子的基因工程化载体，可逆转免疫治疗耐药。在临床转化与应用方面，单药治疗及联合治疗展现出良好的治疗潜力。探讨溶瘤病毒联合治疗的协同机制，分析临床转化面临的挑战与未来发展方向，可为克服肿瘤免疫耐药提供新思路。

关键词: 溶瘤病毒疗法, 免疫疗法, 抗药性，肿瘤, 纳米粒子

Abstract:

Oncolytic viruses， as an innovative therapy with multiple anti-tumor mechanisms， have shown significant potential in reversing immune therapy resistance. Research on the technological evolution of oncolytic viruses indicates that they gradually overcome tumor drug resistance through mechanism innovation. In the field of tumor immunotherapy， oncolytic virus therapy is undergoing significant technological advancements. It has evolved from early virus selective replication to gene-engineered vectors capable of carrying multiple immune regulatory factors， which can reverse immune therapy resistance. In terms of clinical translation and application， both monotherapy and combination therapy have demonstrated good therapeutic potential. Exploring the synergistic mechanisms of oncolytic virus combination therapy and analyzing the challenges and future development directions in clinical translation can provide new ideas for overcoming tumor immune resistance.

Key words: Oncolytic virotherapy, Immunotherapy, Drug resistance， neoplasm, Nanoparticles

高玉琼, 刁杰, 殷红. 溶瘤病毒在逆转肿瘤免疫治疗耐药中的研究进展[J]. 国际肿瘤学杂志, 2026, 53(7): 434-438.

Gao Yuqiong, Diao Jie, Yin Hong. Research progress of oncolytic viruses in reversing tumor immune therapy resistance[J]. Journal of International Oncology, 2026, 53(7): 434-438.

参考文献 38

[1]	Zhang JY, Chen JH, Lin KZ. Immunogenic cell death-based oncolytic virus therapy: a sharp sword of tumor immunotherapy[J]. Eur J Pharmacol, 2024, 981: 176913. DOI: 10.1016/j.ejphar.2024.176913.
[2]	Reid TR, Oronsky B, Williams J, et al. TGF-β trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistance[J]. J Immunother Cancer, 2024, 12(10): e009613. DOI: 10.1136/jitc-2024-009613.
[3]	Ambegoda P, Jang SRJ. Resistance in oncolytic viral therapy for solid tumors[J]. Appl Math Comput, 2024, 469: 128546. DOI: 10.1016/j.amc.2024.128546.
[4]	Fan Z, Liu Y, Lin XY, et al. Suppression of multiple mouse models of refractory malignancies by reprogramming IL-18 ligand-receptor interaction[J]. Nat Commun, 2025, 16: 6136. DOI: 10.1038/s41467-025-61439-0.
[5]	Liang XM, Li JJ, Chen JH, et al. TAMs-mediated resistance to oncolytic virus M1 in solid tumors[J]. J Immunother Cancer, 2025, 13(11): e012858. DOI: 10.1136/jitc-2025-012858.
[6]	Ma R, Li ZL, Chiocca EA, et al. The emerging field of oncolytic virus-based cancer immunotherapy[J]. Trends Cancer, 2023, 9(2): 122-139. DOI: 10.1016/j.trecan.2022.10.003.
[7]	Davar D, Carneiro BA, Dy GK, et al. Phase Ⅰ study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV-GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors[J]. J Immunother Cancer, 2024, 12(11): e009336. DOI: 10.1136/jitc-2024-009336.
[8]	Mondal M, Guo JG, He P, et al. Recent advances of oncolytic virus in cancer therapy[J]. Hum Vaccin Immunother, 2020, 16(10): 2389-2402. DOI: 10.1080/21645515.2020.1723363.
[9]	Chesney J, Puzanov I, Collichio F, et al. Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipili-mumab alone in metastatic unresectable melanoma[J]. Br J Cancer, 2019, 121(5): 417-420. DOI: 10.1038/s41416-019-0530-6.
[10]	Shen Y, Bai X, Zhang Q, et al. Oncolytic virus VG161 in refractory hepatocellular carcinoma[J]. Nature, 2025, 641(8062): 503-511. DOI: 10.1038/s41586-025-08717-5.
[11]	Qiu Y, Qin A, Zhao R, et al. Oncolytic virotherapy stimulates anti- tumor immune response and demonstrates activity in advanced sarcoma: report of two cases[J]. Oncol Lett, 2024, 27(6): 244. DOI: 10.3892/ol.2024.14377.
[12]	Chouljenko DV, Murad YM, Lee IF, et al. Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1[J]. Mol Ther Oncolytics, 2023, 28: 334-348. DOI: 10.1016/j.omto.2023.02.003.
[13]	Zhong L, Gan L, Wang B, et al. Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients[J]. Cell, 2025, 188(4): 1119-1136.e23. DOI: 10.1016/j.cell.2024.12.010. pmid: 39826543
[14]	Dan J, Cai J, Zhong YQ, et al. Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine[J]. Cell Rep Med, 2023, 4(10): 101229. DOI: 10.1016/j.xcrm.2023.101229.
[15]	Geisler A, Hazini A, Heimann L, et al. Coxsackievirus B3—its potential as an oncolytic virus[J]. Viruses, 2021, 13(5): 718. DOI: 10.3390/v13050718.
[16]	Shen YN, Song W, Lin DN, et al. VG161 activates systemic antitumor immunity in pancreatic cancer models as a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes[J]. J Med Virol, 2023, 95(1): e28108. DOI: 10.1002/jmv.28108.
[17]	Zhang Y, Shi XY, Shen YF, et al. Nanoengineering-armed oncolytic viruses drive antitumor response: progress and challenges[J]. MedComm (2020), 2024, 5(10): e755. DOI: 10.1002/mco2.755.
[18]	Chouljenko DV, Ding J, Lee IF, et al. Induction of durable antitumor response by a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes[J]. Biomedicines, 2020, 8(11): 484. DOI: 10.3390/biomedicines8110484.
[19]	Shi WQ, Xu W, Song LY, et al. A tumor-conditional IL-15 safely synergizes with immunotherapy to enhance antitumor immune responses[J]. Mol Ther, 2024, 32(12): 4482-4496. DOI: 10.1016/j.ymthe.2024.10.021. pmid: 39489922
[20]	Dai WW, Tian RT, Yu LB, et al. Overcoming therapeutic resistance in oncolytic herpes virotherapy by targeting IGF2BP3-induced NETosis in malignant glioma[J]. Nat Commun, 2024, 15(1): 131. DOI: 10.1038/s41467-023-44576-2. pmid: 38167409
[21]	Appolloni I, Alessandrini F, Menotti L, et al. Specificity, safety, efficacy of EGFRvⅢ-retargeted oncolytic HSV for xenotransplanted human glioblastoma[J]. Viruses, 2021, 13(9): 1677. DOI: 10.3390/v13091677.
[22]	Rivera-Orellana S, Bautista J, Palacios-Zavala D, et al. Oncolytic virotherapy and tumor microenvironment modulation[J]. Clin Exp Med, 2025, 25(1): 256. DOI: 10.1007/s10238-025-01691-2. pmid: 40685482
[23]	Balasubramanian A, Marceaux C, Kanwal S, et al. Effects of CVA21, an oncolytic virus, in combination with pembrolizumab on immunogenicity and the tumor microenvironment in advanced NSCLC: a phase Ⅰ/Ⅱ trial[J]. Clin Cancer Res, 2025, 31(22): 4644-4654. DOI: 10.1158/1078-0432.CCR-25-1449.
[24]	Heiniö C, Clubb J, Kudling T, et al. Effective combination immunotherapy with oncolytic adenovirus and anti-PD-1 for treatment of human and murine ovarian cancers[J]. Diseases, 2022, 10(3): 52. DOI: 10.3390/diseases10030052.
[25]	Zhu YF, Zhang XF, Jin JQ, et al. Engineered oncolytic virus coated with anti-PD-1 and alendronate for ameliorating intratumoral T cell hypofunction[J]. Exp Hematol Oncol, 2025, 14(1): 16. DOI: 10.1186/s40164-025-00611-0. pmid: 39955603
[26]	Wu YY, Chen MS, Liao TL, et al. Oncolytic viruses in cancer therapy: exploring the mechanisms and clinical potential of mammalian and avian reoviruses[J]. Tungs' Med J, 19(1): 19-26. DOI: 10.4103/ETMJ.ETMJ-D-24-00040.
[27]	Hensen LCM, Hoeben RC, Bots STF. Adenovirus receptor expression in cancer and its multifaceted role in oncolytic adenovirus therapy[J]. Int J Mol Sci, 2020, 21(18): 6828. DOI: 10.3390/ijms21186828.
[28]	Bommareddy PK, Wakimoto H, Martuza RL, et al. Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival[J]. J Immunother Cancer, 2024, 12(4): e008880. DOI: 10.1136/jitc-2024-008880.
[29]	Shen Y, Rahimian S, Qin A, et al. 994MO The updated report of phase Ⅰ trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/Rα payloads, in patients with advanced solid tumors[J]. Ann Oncol, 2024, 35(Suppl_2): S677. DOI: 10.1016/j.annonc.2024.08.1053.
[30]	杜莎, 姜珂, 丁铲, 等. 溶瘤新城疫病毒: 肿瘤免疫治疗时代的新机遇[J]. 中国科学: 生命科学, 2021, 51(12): 1623-1636.
[31]	Wang J, Zhu MT, Nie GJ. Biomembrane-based nanostructures for cancer targeting and therapy: from synthetic liposomes to natural biomembranes and membrane-vesicles[J]. Adv Drug Deliv Rev, 2021, 178: 113974. DOI: 10.1016/j.addr.2021.113974.
[32]	Zhao YB, Le TMD, Hong J, et al. Smart accumulating dual-targeting lipid envelopes equipping oncolytic adenovirus for enhancing cancer gene therapeutic efficacy[J]. ACS Nano, 2024, 18(41): 27869-27890. DOI: 10.1021/acsnano.4c02165. pmid: 39356167
[33]	Feng XY, Liu WM, Jia XY, et al. Antitumor effect and immunomodulatory mechanism of "Oncolytic Extracellular Vesicles"[J]. Nano Lett, 2024, 24(31): 9598-9607. DOI: 10.1021/acs.nanolett.4c02279. pmid: 38922640
[34]	Omolekan TO, Folahan JT, Tesfay MZ, et al. Viral warfare: unleashing engineered oncolytic viruses to outsmart cancer's defenses[J]. Front Immunol, 2025, 16: 1618751. DOI: 10.3389/fimmu.2025.1618751.
[35]	丁浩, 应劲涛, 付茂勇. CAR-T在食管鳞状细胞癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 231-235. DOI: 10.3760/cma.j.cn371439-20221123-00045.
[36]	Liu YY, Zheng YX, Deng TY, et al. Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy[J]. Front Oncol, 2022, 12: 1037934. DOI: 10.3389/fonc.2022.1037934.
[37]	Zhang YL, Qian L, Chen K, et al. Intraperitoneal oncolytic virotherapy for patients with malignant ascites: characterization of clinical efficacy and antitumor immune response[J]. Mol Ther Oncolytics, 2022, 25: 31-42. DOI: 10.1016/j.omto.2022.03.003.
[38]	张鸿森. 缺氧复制型溶瘤腺病毒联合经导管动脉栓塞治疗肝细胞癌的机理探究和疗效评估[D]. 武汉: 华中科技大学, 2019, 1-96. DOI: 10.27157/d.cnki.ghzku.2019.005165.